Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Fuerst

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
Antiviral Research|January 2, 2019
In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infectionLaurent Mailly, Florian Wrensch, Laura Heydmann, et al.
Nature Communications|July 5, 2023
Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodiesMatthew C Metcalf, Benjamin M Janus, Rui Yin, et al.
Nature|June 6, 1991
New use of BCG for recombinant vaccinesC K Stover, V F de la Cruz, T R Fuerst, et al.
Journal of Virology|June 1, 1996
Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus AnkaraV M Hirsch, T R Fuerst, G Sutter, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
Glycoengineered recombinant alpha1-antitrypsin results in comparable <i>in vitro</i> and <i>in vivo</i> activities to human plasma-derived proteinFrances Rocamora, Sanne Schoffelen, Johnny Arnsdorf, et al.
Biotechnology and Bioengineering|July 1, 2026
Glycoengineered Recombinant Alpha1-Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma-Derived ProteinFrances Rocamora, Chen-Lin Hsieh, Sanne Schoffelen, et al.
Journal of Functional Biomaterials|January 20, 2023
Skin Vaccination with Ebola Virus Glycoprotein Using a Polyphosphazene-Based Microneedle Patch Protects Mice against Lethal ChallengeAndrey Romanyuk, Ruixue Wang, Alexander Marin, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
The conserved bridging domain on HCV E1E2 glycoprotein complex is targeted by neutralizing antibodies from diverse lineagesFang Chen, Yen Thi Kim Nguyen, Yi-Zong Lee, et al.
Advances in Experimental Medicine and Biology|January 1, 1996
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidatesB Moss, M W Carroll, L S Wyatt, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2022
Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidateRuixue Wang, Saori Suzuki, Johnathan D Guest, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Antiviral Research|January 2, 2019
In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infectionLaurent Mailly, Florian Wrensch, Laura Heydmann, et al.
Nature Communications|July 5, 2023
Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodiesMatthew C Metcalf, Benjamin M Janus, Rui Yin, et al.
Nature|June 6, 1991
New use of BCG for recombinant vaccinesC K Stover, V F de la Cruz, T R Fuerst, et al.
Journal of Virology|June 1, 1996
Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus AnkaraV M Hirsch, T R Fuerst, G Sutter, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2024
Glycoengineered recombinant alpha1-antitrypsin results in comparable <i>in vitro</i> and <i>in vivo</i> activities to human plasma-derived proteinFrances Rocamora, Sanne Schoffelen, Johnny Arnsdorf, et al.
Biotechnology and Bioengineering|July 1, 2026
Glycoengineered Recombinant Alpha1-Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma-Derived ProteinFrances Rocamora, Chen-Lin Hsieh, Sanne Schoffelen, et al.
Journal of Functional Biomaterials|January 20, 2023
Skin Vaccination with Ebola Virus Glycoprotein Using a Polyphosphazene-Based Microneedle Patch Protects Mice against Lethal ChallengeAndrey Romanyuk, Ruixue Wang, Alexander Marin, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
The conserved bridging domain on HCV E1E2 glycoprotein complex is targeted by neutralizing antibodies from diverse lineagesFang Chen, Yen Thi Kim Nguyen, Yi-Zong Lee, et al.
Advances in Experimental Medicine and Biology|January 1, 1996
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidatesB Moss, M W Carroll, L S Wyatt, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2022
Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidateRuixue Wang, Saori Suzuki, Johnathan D Guest, et al.
Pageof 13